Data shown is for informational purposes only and does not constitute investment advice. TopFund is not SEBI-registered. Consult a SEBI-registered advisor before investing.
Sai Parenteral's
Price Band
₹372.0–392.0
Issue Size
₹408.79 Cr
Lot Size
38 shares
Min Investment
₹14,896
GMP
+₹0.0 (0.0%)
Issue Price
₹392.0
calendar_month Important Dates
bar_chart Subscription Status
Subscription data unavailable
trending_up Grey Market Premium (GMP)
GMP
₹0.0
GMP %
0.0%
Est. Listing
₹392.0
schedule Updated: 14 Jul 2026 15:52
Share GMP:
business About the Company
Incorporated in 2001, Sai Parenteral's Ltd. is a diversified pharmaceutical formulations company with expertise in research, development, and manufacturing. The company operates in two segments: Branded Generic Formulations and Contract Development and Manufacturing Organisation (CDMO) products and services for domestic and international markets. The product portfolio spans multiple therapeutic areas including cardiovascular, neuropsychiatry, anti-diabetic, respiratory health, antibiotics, gastroenterology, vitamins, minerals and supplements (VMS), analgesics, and dermatology. Offerings are across dosage forms such as injectables, tablets, capsules, liquid orals, and ointments. Sai Parenteral's serves a wide customer base comprising central and state government agencies, pharmaceutical companies, public and private hospitals, and super stockists in India. The company entered exports in FY 2023 after acquiring two internationally accredited facilities in Hyderabad, Telangana, and now supplies to regulated and semi-regulated markets in Australia, New Zealand, Southeast Asia, the Middle East, and Africa. The company owns and operates five manufacturing facilities in India. Four are located in Hyderabad, Telangana, comprising a GMP-compliant injectable unit, a WHO-GMP injectable unit, a TGA-Australia and PIC/S accredited solid oral dosage unit, and a WHO-GMP cephalosporin facility. Its wholly owned subsidiary, Revat Laboratories, operates a GMP-certified facility in Ongole, Andhra Pradesh. As of August 31, 2025, Sai Parenteral's Ltd. employed 277 full-time employees.
payments Company Financials (₹ Cr)
As of 2025-09-30
| Period Ended | 30 Sep 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 376.24 | 272.39 | 268.10 | 133.96 |
| Total Income | 89.43 | 163.74 | 155.18 | 97.03 |
| Profit After Tax | 7.76 | 14.43 | 8.42 | 4.38 |
| EBITDA | 16.24 | 39.44 | 31.70 | 17.64 |
| NET Worth | 209.37 | 95.78 | 76.40 | 31.49 |
| Reserves and Surplus | 188.84 | 80.36 | 61.30 | 24.34 |
| Total Borrowing | 76.07 | 93.95 | 118.79 | 68.55 |
Key Ratios
EPS
₹5.43
NAV
₹35.98
ROE
16.82%
ROCE
28.92%
RoNW
15.09%
P/B Value
10.89
P/E Ratio
72.19
Market Cap
₹1731.83 Cr
PAT Margin
8.88%
Promoters
Anil Kumar Karusala, Vijitha Gorrepati and Karusala Aruna
Objects of the Issue
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects: # Issue Objects Est Amt (₹ Cr.) 1 Capacity expansion and upgradation of manufacturing facilities 110.80 2 Establishment of a new R&D Centre; 18.02 3 Repayment / prepayment of certain outstanding borrowings 14.30 4 Working capital requirements 33.00 5 Investment in wholly owned subsidiary, Sai Parenterals Pte Limited (Singapore), in relation to the proposed acquisition of Noumed Pharmaceuticals Pty Limited (Australia); and 35.64 6 General corporate purposes 44.74 7 Issue Expenses 40.84 Total 297.34
info Issue Details
pie_chart Investor Allocation
Registrar
Lead Managers / Book Running
timeline IPO Timeline
Open
24 Mar 2026
Close
27 Mar 2026
Allotment
30 Mar 2026
Listing
02 Apr 2026